

B7-H3 (4Ig) /B7-H3b

Catalog # PVGS1802

Product Information

Primary Accession Species	Q5ZPR3-1 Human
Sequence	Gly27-Thr461
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μ g by the LAL method.
Biological Activity	Immobilized B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human (Cat.No.: Z03891) at 1 μ g/ml (100 μ l/Well) on the plate can bind Biotinylated Anti-B7-H3 Antibody, hFc Tag
Expression System	HEK293
Theoretical Molecular Weight	73.4 kDa
Formulation	Lyophilized from a 0.22 μ m filtered solution in PBS, pH 7.4.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 μ g/ml.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers. B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig B7 H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.
--------------------------	--

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.